09877 JENSCARE-B
- 4.320
- -0.190-4.21%
JENSCARE-B News
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
健世科技-B：2023年報
Jenscare Scientific's LuX-Valve Application Not Approved by NMPA, Share Prices Drop 11%
Jenscare Scientific (HKG:9877) said the National Medical Products Administration (NMPA) did not approve LuX-Valve during technical evaluation, according to a Thursday filing on the Hong Kong bourse. L
Changes in Hong Kong stocks | Jianshi Technology-B (09877) rose more than 22%, the company has abundant cash flow, and the global commercialization of LUX-Valve continues to expand
Jianshi Technology-B (09877) rose by more than 22%. As of press release, it was up 19.05% to HK$4, with a turnover of HK$25.9636 million.
Health Check: How Prudently Does Jenscare Scientific (HKG:9877) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Jianshi Technology-B (09877) released annual results with R&D expenditure of 288 million yuan, and the product received wide recognition from around the world
Jianshi Technology-B (09877) announced results for the year ended December 31, 2023, other revenue and revenue...
JENSCARE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Jianshi Technology-B (09877.HK): Converting 179 million unlisted shares to 179 million H shares of the company
Gelonghui March 25 | Jianshi Technology-B (09877.HK) announced that 178,715,577 unlisted shares will be converted to 178,715,577 H shares on March 25, 2024.
Jenscare Scientific's Mitral Valve Device Completes Enrollment for Confirmatory Clinical Trials
Jenscare Scientific (HKG:9877) said its clip-based TMVr system completed the enrollment for confirmatory clinical trial and the one-month clinical follow-up, according to a Monday Hong Kong bourse fil
Jianshi Technology-B (09877.HK): JensClip completed confirmatory clinical enrollment and one-month follow-up
Gelonghui March 25 | Jianshi Technology-B (09877.HK) announced that recently, JenSclip, a transcatheter mitral valve repair clamping system independently developed by the company to treat severe mitral valve reflux, has completed confirmatory clinical enrollment and completed a one-month clinical follow-up with excellent clinical results. JensClip uses a locking mechanism with a claw wall and is equipped with a structural design that can grip the flap multilaterally, which can effectively reduce reflux. Furthermore, its delivery system design allows doctors to control the instrument in a 360-degree range, which is easy to use and highly flexible. The company is continuing to promote a variety of self-developed innovative medical treatments
Jianshi Technology-B (09877.HK): Complete the full circulation of H shares
Gelonghui March 25 | Jianshi Technology-B (09877.HK) announced that on March 25, 2024, 178,715,577 unlisted shares have been converted to H shares, and the converted H shares will be listed on the Stock Exchange at 9:00 a.m. on March 25, 2024. After the relevant domestic arrangements and procedures are completed, participating domestic shareholders can trade the converted H shares.
Jenscare Scientific Secures HKEX Nod for H Share Circulation
Jenscare Scientific (HKG:9877) said the Hong Kong Stock Exchange's listing committee has granted permission for the conversion of 178,715,577 unlisted company's shares into H shares, according to a Ma
Jianshi Technology-B (09877): The Stock Exchange granted listing approval to implement full circulation of H shares
Jianshi Technology-B (09877) issued an announcement. The company has applied to the Stock Exchange Listing Committee to approve the company in accordance with the conversion and...
Jianshi Technology-B (09877.HK) held a board meeting on March 27 to consider and approve the annual results
Gelonghui March 15 | Jianshi Technology-B (09877.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve the Group's annual results and announcements for the year ended 31 December 2023, and consider recommending the payment of a final dividend (if any) and other matters.
JENSCARE-B: NOTICE OF BOARD MEETING
Jianshi Technology-B (09877): The China Securities Regulatory Commission issued a filing notice on the company's application for full circulation of H shares
Jianshi Technology-B (09877) issued an announcement. The company recently addressed the China Securities Regulatory Commission on behalf of several shareholders of the company...
Zhongtai Securities: Edward Evoque received FDA approval and continues to be optimistic about the commercialization prospects of tricuspid valve intervention
Recently, Edward Life Sciences announced that its tricuspid valve product Evoque has been approved by the FDA for marketing. This is the first FDA-approved tricuspid valve replacement product.
Pleasing Signs As A Number Of Insiders Buy Jenscare Scientific Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Jenscare Scientific Co., Ltd.'s (HKG:9877) case, it's fantastic news for sha
Jianshi Technology-B (09877.HK): Chairman, Executive Director and Senior Management increase their shareholding
Gelonghui, January 26, 丨 Jianshi Technology-B (09877.HK) announced that as of January 26, 2024, Lu Shiwen (Chairman of the Board, Executive Director and CEO) and Pan Fei (Executive Director and Chief Financial Officer) have each purchased several H shares of the company with their own capital at a cost of approximately HK$3.291,000 and HK$581,000, respectively. The total cost is approximately HK$3.872 million. According to Mr. Lu and Mr. Pan, the increase in equity is based on the smooth progress of the global commercialization of the company's products. Their confidence in the company's long-term development potential is not ruled out, and it is not ruled out that it will advance in a timely manner in accordance with laws and regulations
[Hong Kong Stock Connect] Jianshi Technology (09877) received an increase in H shares totaling HK$3.872 million from the CEO and CFO
Jinwu Financial News | Jianshi Technology (09877) announced that as of January 26, 2024, Chairman of the Board of Directors, Executive Director and CEO Lui Shiwen, and Executive Director and Chief Financial Officer Pan Fei had each purchased several H shares of the company with their own funds at a cost of about HK$3.291,000 and HK$581,000 respectively, with a total cost of about HK$3.882 million.
Analysis
Price Target
No Data
